Full Press Release Details
Inc. Reports SECOND Quarter AND SIX MONTH 2023 Financial Results and Provides Business Update
Call Scheduled for Today at 8:30 a.m. Eastern Time
Heights, NJ - August 8, 2023 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and
commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial
results for the second quarter and six months ended June 30, 2023 and provided an update on recent business events.
Corporate Highlights:
Todisco, CorMedix CEO, commented, "we are pleased with the progress that we have made toward our goal of achieving a potential
FDA approval of DefenCath later this year. With the recent financing completed, we believe CorMedix is in a strong financial position
and we are heavily focused on operational execution and commercial preparedness ahead of our target action date in November. We look
forward to providing updates as we aim to deliver on our commitment to reducing the risk of infections in patients receiving hemodialysis
via central venous catheters."
Quarter and Six Month 2023 Financial Highlights
the second quarter of 2023, CorMedix recorded a net loss of $11.3 million, or $0.25 per share, compared with a net loss of $7.6 million,
or $0.19 per share, in the second quarter of 2022, an increase of $3.7 million or 48%. The higher net loss recognized in 2023 compared
with 2022 included an increase in both SG&A expenses and R&D expenses versus the second quarter of 2022.
expenses in the second quarter of 2023 increased approximately 43% to $11.8 million, compared with $8.3 million in the second quarter
of 2022. R&D expense increased approximately 49% to $4.8 million compared with $3.2 million in the second quarter of 2022, mainly
due to an increase in costs related to the manufacturing of DefenCath prior to its potential marketing approval. SG&A expense increased
approximately 39% to $7.0 million compared with $5.1 million in the second quarter of 2022. This increase was driven primarily by an
increase in costs related to market research studies and pre-launch activities in preparation for the potential marketing approval of
the six months ended June 30, 2023, CorMedix recorded a net loss of $21.8 million, or $0.49 per share, compared with a net loss of $14.6
million, or $0.38 per share, in the first half of 2022. Operating expenses in the first half of 2023 were $22.8 million, compared to
$15.3 million in the first half of 2022, an increase of approximately 49%. This increase was primarily due to costs related to market
research studies, pre-launch activities in preparation for the potential marketing approval of DefenCath and costs for the manufacturing
of DefenCath prior to its potential marketing approval.
Company reported cash and short-term investments of $52.4 million at June 30, 2023, excluding restricted cash. In addition, CorMedix
received approximately $43.2 million in net proceeds from its equity financing that closed in July of 2023. The Company believes that
it has sufficient resources to fund operations for at least twelve months from the filing of its Quarterly Report on Form 10-Q for the
quarter ended June 30, 2023.
management team of CorMedix will host a conference call and webcast today, August 8, 2023, at 8:30 AM Eastern Time, to discuss recent
corporate developments and financial results. Call details and dial-in information are as follows:
August 8th @ 8:30am ET
| Domestic: | 1-877-423-9813 |
| International: | 1-201-689-8573 |
| Conference ID: | 13740152 |
| Webcast: | Webcast Link |
Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of
life-threatening conditions and diseases. The Company is focused on developing its lead product DefenCath , a novel, non-antibiotic
antimicrobial solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous
catheters in patients undergoing chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious
Disease Product (QIDP), and the original New Drug Application (NDA) received priority review in recognition of its potential to address
an unmet medical need. QIDP provides for an additional five years of marketing exclusivity, which will be added to the five years granted
to a New Chemical Entity upon approval of the NDA. CorMedix also committed to conducting a clinical study in pediatric patients using
a central venous catheter for hemodialysis when the NDA is approved, which will add an additional six months of marketing exclusivity
when the study is completed. CorMedix received a second Complete Response Letter from the FDA last August related to deficiencies at
both its primary contract manufacturer and its supplier of heparin API. After receiving guidance from FDA at a Type A meeting in April
of 2023, the NDA for DefenCath was resubmitted. In June of 2023, the resubmitted NDA was accepted for filing by the FDA. CorMedix also
intends to develop DefenCath as a catheter lock solution for use in other patient populations, and the Company is working with top-tier
researchers to develop taurolidine-based therapies for rare pediatric cancers. For more information visit: www.cormedix.com.
press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that
are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations,
beliefs, goals, plans or CorMedix's prospects, including, but not limited to, CorMedix's future financial position, financing
plans, future revenues, projected costs and the sufficiency of our cash and short-term investments to fund our operations should be considered
forward-looking statements. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety
of important factors, including: the risks and uncertainties related to market conditions; the ability to secure final FDA approval prior
to July 1, 2024; CorMedix's ability to manage its cash resources and the impact on current, planned or future research; the ability
to achieve commercial preparedness ahead of the target action date in November 2023; and that preclinical results are not indicative
of success in clinical trials and might not be replicated in any subsequent studies or trials. These and other risks are described in
greater detail in CorMedix's filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov
or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements,
and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these
forward-looking statements, except as required by law.
Inc. and SubsidiarIES
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenue: | ||||||||||||||||
| Net sales | $ | - | $ | 21,253 | $ | - | $ | 28,889 | ||||||||
| Cost of sales | - | (332 | ) | - | (1,859 | ) | ||||||||||
| Gross profit (loss) | - | 20,921 | - | 27,030 | ||||||||||||
| Operating Expenses: | ||||||||||||||||
| Research and development | (4,794,758 | ) | (3,209,471 | ) | (8,202,260 | ) | (5,497,058 | ) | ||||||||
| Selling, general and administrative | (7,009,824 | ) | (5,051,895 | ) | (14,619,501 | ) | (9,802,778 | ) | ||||||||
| Total Operating Expenses | (11,804,582 | ) | (8,261,366 | ) | (22,821,761 | ) | (15,299,836 | ) | ||||||||
| Loss From Operations | (11,804,582 | ) | (8,240,445 | ) | (22,821,761 | ) | (15,272,806 | ) | ||||||||
| Other Income (Expense): | ||||||||||||||||
| Total Other Income | 530,964 | 49,989 | 980,917 | 48,156 | ||||||||||||
| Loss before income taxes | (11,273,618 | ) | (8,190,456 | ) | (21,840,844 | ) | (15,224,650 | ) | ||||||||
| Tax benefit | - | 585,617 | - | 585,617 | ||||||||||||
| Net Loss | (11,273,618 | ) | (7,604,839 | ) | (21,840,844 | ) | (14,639,033 | ) | ||||||||
| Other Comprehensive Income (Loss): | ||||||||||||||||
| Total Other Comprehensive Income (Loss) | (10,535 | ) | (10,402 | ) | 7,954 | (47,611 | ) | |||||||||
| Comprehensive Loss | $ | (11,284,153 | ) | $ | (7,615,241 | ) | $ | (21,832,890 | ) | $ | (14,686,644 | ) | ||||
| Net Loss Per Common Share - Basic and Diluted | $ | (0.25 | ) | $ | (0.19 | ) | $ | (0.49 | ) | $ | (0.38 | ) | ||||
| Weighted Average Common Shares Outstanding - Basic and Diluted | 45,365,635 | 39,761,754 | 44,731,838 | 39,008,590 |
CONDENSED CONSOLIDATED
| June 30, | December 31, | |||||||
| 2023 | 2022 | |||||||
| ASSETS | ||||||||
| Cash, cash equivalents and restricted cash | $ | 19,888,972 | $ | 43,374,745 | ||||
| Short-term investments | $ | 32,701,210 | $ | 15,644,062 | ||||
| Total Assets | $ | 57,032,780 | $ | 62,038,259 | ||||
| Total Liabilities | $ | 7,981,671 | $ | 6,978,523 | ||||
| Accumulated deficit | $ | (297,201,630 | ) | $ | (275,360,786 | ) | ||
| Total Stockholders' Equity | $ | 49,051,109 | $ | 55,059,736 |
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS
| Six Month Periods Ended June 30, | ||||||||
| 2023 | 2022 | |||||||
| Cash Flows from Operating Activities: | ||||||||
| Net loss | $ | (21,840,844 | ) | $ | (14,639,033 | ) | ||
| Net cash used in operating activities | (18,966,316 | ) | (12,206,457 | ) | ||||
| Cash Flows from Investing Activities: | ||||||||
| Net cash used in investing activities | (17,072,611 | ) | (3,593,220 | ) | ||||
| Cash Flows from Financing Activities: | ||||||||
| Net cash provided by financing activities | 12,550,623 | 11,415,372 | ||||||
| Net Decrease in Cash and Cash Equivalents | (23,485,773 | ) | (4,397,860 | ) | ||||
| Cash and Cash Equivalents and Restricted Cash - Beginning of Period | 43,374,745 | 53,551,277 | ||||||
| Cash and Cash Equivalents and Restricted Cash - End of Period | $ | 19,888,972 | $ | 49,153,417 |